Status: Recruiting
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: May 13, 2026Locations: 21
Eligibility criteria
Patients must have histologically or cytologically confirmed HCL/HCLv after puri... [+15]
Patients who have received prior venetoclax [+6]